

PRODUCT PIPELINE

BWXT Medical has a deep and rich history of radiopharmaceutical innovation, development, and manufacturing. Selected products in development include:

Tc-99m Generators

BWXT's scientists and engineers have developed an innovative solution to produce molybdenum-99 (Mo-99), the parent isotope of technetium-99m (Tc-99m), which is used in over 40 million medical procedures across the globe each year.

Stability of Supply

Historically, Mo-99 has been produced within aging research reactors using uranium as the starting material. BWXT's new approach will offer a step change in dependability of supply and includes:



Natural Molybdenum target fabrication

No proliferation risk, no uranium.



Irradiation at commercial power reactors

Highly reliable sources.



Co-located processing and generator facility

**No fission or costly waste.
Streamlined operations from irradiation to production.**



Drop-in replacement generators

**No need for customers to change –
same activity, quality, and method of elution.**

Targeted Therapies



BWXT Medical is working with pharmaceutical partners to develop radiotherapeutic isotopes that can be used in targeted radionuclide therapies (TRTs) for the treatment of diseases such as cancer.

High Purity Actinium-225 (Ac-225)

Ac-225 is one of the rarest medical isotopes on earth. When it undergoes radioactive decay, it releases a highly cytotoxic dose of alpha particles that can effectively kill tumor cells without causing harm to the healthy tissue that surrounds them.



After receiving approval, Mo-99 produced at Ontario Power Generation's Darlington Nuclear Generating Station and in the University of Missouri Research Reactor (MURR), will be processed at BWXT Medical's facility and incorporated into Tc-99m generators for delivery to radiopharmacies and hospitals across North America.

People Strong
INNOVATION DRIVEN >

BWXT Medical Ltd. provides its customers, who conduct life-saving medical procedures for patients around the world, the benefit of decades of experience in the development, processing, packaging and delivery of medical isotopes, pharmaceuticals and medical devices. Headquartered in Kanata, Ontario, BWXT Medical employs approximately 300 highly skilled people in Kanata and Vancouver, British Columbia. BWXT Medical is part of the commercial operations segment of BWX Technologies, Inc. (NYSE:BWXT), headquartered in Lynchburg, Virginia, U.S.A. BWXT is a leading supplier of nuclear components and fuel to the U.S. government; provides technical and management services to support the U.S. government in the operation of complex facilities and environmental remediation activities; and supplies precision manufactured components, services and fuel for the commercial nuclear power industry. With approximately 6,600 employees, BWXT has 12 major operating sites in the U.S. and Canada. In addition, BWXT joint ventures provide management and operations at more than a dozen U.S. Department of Energy and NASA facilities. Follow us on Twitter @BWXTech and learn more at www.bwxt.com.

The information contained herein is provided for general information purposes only and is not intended nor to be construed as a warranty, an offer, or any representation of contractual or other legal responsibility.

The products and services described herein are provided by the subsidiaries of BWX Technologies, Inc.

© 2022 BWX Technologies, Inc. All rights reserved.



BWXT Medical

447 March Road
Ottawa, ON, Canada K2K 1X8

Regional Office

4004 Wesbrook Mall
Vancouver, BC, Canada V6T 2A3

Customer Service

isotopeorders@bwxt.com
North America: +1.800.267.6211
International: +1.613.963.2621
General Emergency: +1.613.963.2300